More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children

Table 3

Metabolic parameters of patients grouped according to the GH treatment regimen (group A and group B) at baseline and after 12 months of treatment.

	7 doses per week; (group A); 16 patients; baseline	7 doses per week; (group A); 16 patients; 12 months		3 doses per week; (group B); 16 patients; baseline	3 doses per week; (group B); 16 patients; 12 months
	Mean ± SD	Mean ± SD		Mean ± SD	Mean ± SD
Fasting glucose (mmol/L)	4 ± 0.65	4.77 ± 0.39	0.001	4.17 ± 0.45	4.51 ± 0.35	0.181
Fasting insulin (IU/mL)	2.9 ± 2.2	9.2 ± 5.4	<0.001	2.8 ± 2.2	5.7 ± 2.4	0.026
HbA1c (%)	5.1 ± 0.3	5.2 ± 0.3	0.072	5.3 ± 0.3	5.2 ± 0.2	0.189
Homa-IR	0.52 ± 0.41	1.98 ± 1.20	<0.001	0.53 ± 0.41	1.16 ± 0.53	0.019
ISI-Matsuda	9.65 ± 0.82	8.59 ± 0.83	<0.001	9.03 ± 1.63	8.81 ± 1.57	0.095
DIo	4.48 ± 1.81	2.46 ± 1.27	0.001	4.68 ± 1.39	4.49 ± 1.30	0.057
Total cholesterol (mmol/L)	4.12 ± 0.76	4.07 ± 0.78	0.521	3.98 ± 0.51	3.87 ± 0.58	0.679
HDL cholesterol (mmol/L)	1.58 ± 0.44	1.54 ± 0.44	0.489	1.65 ± 0.31	1.86 ± 0.45	0.094
LDL cholesterol (mmol/L)	2.84 ± 0.53	2.84 ± 0.55	0.961	2.11 ± 0.36	1.95 ± 0.61	0.298
Triglycerides (mmol/L)	1.50 ± 0.41	1.54 ± 0.61	0.760	1.38 ± 0.52	1.22 ± 0.30	0.206

DIo: oral disposition index.